25 years of small molecular weight kinase inhibitors: potentials and limitations.
作者： Doriano Fabbro
关键词:
摘要: … With a few exceptions, like the rapalogs (everolimus and temsirolimus) and trametinib, all of the small molecular weight kinase inhibitors are directed toward the ATP-binding site. The …
sci-hub.se 
researchgate.net 参考文章(161)
D. Fabbro, G. Fendrich, V. Guez, T. Meyer, P. Furet, J. Mestan, J. D. Griffin, P. W. Manley, S. W. Cowan-Jacob, Targeted Therapy with Imatinib: An Exception or a Rule? Inhibitors of Protein Kinases and Protein Phosphates. ,vol. 167, pp. 361- 389 ,(2005) , 10.1007/3-540-26670-4_13
Philipp le Coutre, Elena Tassi, Marileila Varella-Garcia, Rossella Barni, Luca Mologni, Gonçalo Cabrita, Edoardo Marchesi, Rosanna Supino, Carlo Gambacorti-Passerini, Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood. ,vol. 95, pp. 1758- 1766 ,(2000) , 10.1182/BLOOD.V95.5.1758.005A41_1758_1766
Antonio Jimeno, Rodabe N Amaria, T. Medina, Dabrafenib in the treatment of advanced melanoma. Drugs of Today. ,vol. 49, pp. 377- 385 ,(2013) , 10.1358/DOT.2013.49.6.1968669
Doriano Fabbro, Sandra W. Cowan-Jacob, Henrik Möbitz, Georg Martiny-Baron, Targeting cancer with small-molecular-weight kinase inhibitors. Methods of Molecular Biology. ,vol. 795, pp. 1- 34 ,(2012) , 10.1007/978-1-61779-337-0_1
Peter Blume-Jensen, Tony Hunter, Oncogenic kinase signalling. Nature. ,vol. 411, pp. 355- 365 ,(2001) , 10.1038/35077225
David Solit, Mark M. Moasser, Qing-Bai She, Andrea Basso, Resistance to Gefitinib in PTEN-Null HER-Overexpressing Tumor Cells Can Be Overcome through Restoration of PTEN Function or Pharmacologic Modulation of Constitutive Phosphatidylinositol 3′-Kinase/Akt Pathway Signaling Clinical Cancer Research. ,vol. 9, pp. 4340- 4346 ,(2003)
Steven K. Hanks, Tony Hunter, Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. The FASEB Journal. ,vol. 9, pp. 576- 596 ,(1995) , 10.1096/FASEBJ.9.8.7768349
Juan-José Ventura, Ángel R. Nebreda, Protein kinases and phosphatases as therapeutic targets in cancer. Clinical & Translational Oncology. ,vol. 8, pp. 153- 160 ,(2006) , 10.1007/S12094-006-0005-0
D. Gomika Udugamasooriya, Sean P. Dineen, Rolf A. Brekken, Thomas Kodadek, A Peptoid "Antibody Surrogate" That Antagonizes VEGF Receptor 2 Activity Journal of the American Chemical Society. ,vol. 130, pp. 5744- 5752 ,(2008) , 10.1021/JA711193X
Xuerong Wang, Shi-Yong Sun, Enhancing mTOR-targeted cancer therapy. Expert Opinion on Therapeutic Targets. ,vol. 13, pp. 1193- 1203 ,(2009) , 10.1517/14728220903225008